Thomas Powles, MD, PhD, and Enrique Grande, MD, PhD, on Urothelial Carcinoma: Atezolizumab and Platinum-Based Chemotherapy
ESMO 2019 Congress
Thomas Powles, MD, PhD, of Queen Mary University of London, and Enrique Grande, MD, PhD, of MD Anderson Cancer Center, Madrid, discuss findings of the phase III IMvigor130 trial on the efficacy and safety of atezolizumab as monotherapy or combined with platinum-based chemotherapy vs placebo plus platinum-based chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (Abstract LBA14).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses results from a long-term follow-up of a cohort treated with docetaxel in the STAMPEDE randomized trial, confirming that the treatment showed benefit in patients with both high- and low-volume disease (Abstract 844O).
Solange Peters, MD, PhD, of the Oncology Department of CHUV, discusses study findings from the first phase III trial to show PD-1 and CTLA-4 inhibition is effective in non–small cell lung cancer, with improved overall survival vs chemotherapy (Abstract LBA4).
Isabelle Ray-Coquard, MD, PhD, on Ovarian Cancer: Olaparib Plus Bevacizumab
Isabelle Laure Ray-Coquard, MD, PhD, of the Centre Leon Bérard, discusses phase III study findings in patients with newly diagnosed, advanced ovarian cancer who received olaparib plus first-line bevacizumab maintenance treatment. Compared with placebo plus bevacizumab, olaparib improved progression-free survival, with the greatest benefit in women with BRCA mutations and positive homologous recombination deficiency status (Abstract LBA2).
Volker Kunzmann, MD, of the University of Würzburg/Comprehensive Cancer Center Mainfranken, discusses the final results of a phase II multicenter trial on the conversion rate in locally advanced pancreatic cancer after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (Abstract 671O).
Aleix Prat, MD, PhD, of Hospital Clinic de Barcelona, discusses the findings of a meta-analysis showing that the HER2-E subtype may predict pathologic complete response beyond hormone receptor status in HER2-positive early breast cancer (Abstract 248P).
